Responders | Nonresponders | p value | |
---|---|---|---|
1.9 (0.4) | 1.3 (0.4) | 0.3 | |
9.2 (1.0) | 4.4 (0.8) | ||
1436 (332) | 785 (177) | 0.2 | |
12152 (868) | 8838 (1286) | ||
51.0 (3.7) | 42.5 (5.5) | 0.2 | |
48.8 (3.8) | 57.5 (5.5) | 0.2 |
Abbreviation | Phenotype | |
---|---|---|
Plasmacytoid DC | pDC | HLA-DR+, CD123+, CD303+, CD11c-, CD3-, CD14-, CD16-, CD19- |
Conventional DC | cDC | HLA-DR+, CD11c+, CD123-, CD303-, CD3-, CD14-, CD16-, CD19- |
Mature conventional DC | CD86+ DC | CD80+, CD86+, CD83+, HLA-DR+, CD11c+, CD123-, CD303-, CD3-, CD14-, CD16-, CD19- |
Activated mature conventional DC | HLA-DR DC | HLA-DRhi, CD83+, CD80+, CD86+, CD11c+, CD123-, CD303-, CD3-, CD14-, CD16-, CD19- |
Intestinal CD103+ DCs important in maintaining intestinal immune homeostasis | CD103+ DC | CD103+, HLA-DR+, CD11c+, CD123-, CD303-, CD3-, CD14-, CD16-, CD19- |
IBD-uninflamed | IBD-inflamed | p value | |
---|---|---|---|
1.7 (0.2) | 1.7 (0.3) | 0.9 | |
4.5 (0.6) | 7.8 (0.9) | ||
1483 (212) | 1248 (231) | 0.53 | |
11965 (767) | 10918 (767) | 0.33 | |
57.3 (3.5) | 47.1 (3.1) | ||
42.3 (3.4) | 52.8 (3.2) |
IBD-before | IBD-after | p value | |
---|---|---|---|
1.7 (0.3) | 1.3 (0.2) | 0.32 | |
7.8 (0.9) | 4.5 (0.9) | ||
1248 (231) | 826 (219) | 0.29 | |
10918 (767) | 12141 (616) | 0.09 | |
47.1 (3.1) | 48.1 (4.5) | 0.86 | |
52.8 (3.2) | 50.7 (4.8) | 0.75 |
Before treatment | After treatment | |
---|---|---|
(week 0) | (week 12) | |
SCCAI | 8.4 (0.9) | 3.1 (0.5) |
CRP (mg/l) | 8.8 (2.9) | 7.8 (2.4) |
Fecal calprotectin (mg/kg) | 351 (41.7) | 254 (58.2) |
Endoscopic Mayo Score | 2.4 (0.1) | 1.5 (0.3) |
HBSI | 9.5 (1.3) | 3.3 (0.8) |
CRP (mg/l) | 17.5 (3.1) | 10.5 (3.6) |
Fecal calprotectin (mg/kg) | 341 (40) | 209 (48) |
SES-CD | 12.9 (1.1) | 5.5 (1.8) |
Number | Mean | |
---|---|---|
40 | ||
16 | ||
Female/male | 8/8 | |
Age (years) | 38.6 | |
(13.7) | ||
Disease duration (years) Age at diagnosis (years) | 7.1 (6.5) 31.4 | |
(14.5) | ||
Smokers | 5 | |
Ex-smokers | 3 | |
Nonsmokers | 8 | |
Location of Crohn’s disease | 16 | |
I. L1 (ileal) | ||
II. L2 (colonic) | ||
III. L3 (ileocolonic) | ||
IV. L4 (isolated upper disease) | ||
Concomitant medications | 13 | |
I. Aminosalicylates | ||
II. Corticosteroid | ||
III. Azathioprine | ||
IV. Azathioprine + corticosteroids | ||
V. None | ||
14 | ||
Female/male | 8/6 | |
Age (years) | 39.2 (12) | |
Disease duration (years) | 5.6 (2.8) | |
Age at diagnosis (years) | 33.5 | |
(11.7) | ||
Smokers | 1 | |
Ex-smokers | 3 | |
Nonsmokers | 10 | |
Extent of ulcerative colitis | 14 | |
I. E1 (proctitis) | ||
II. E2 (left sided) | ||
II. E3 (extensive) | ||
Concomitant medications | 14 | |
I. Aminosalicylates | ||
II. Corticosteroid | ||
III. Azathioprine | ||
IV. Azathioprine + corticosteroids | ||
V. None | ||
10 | ||
Female | 6 | |
Male | 4 | |
58.3 | ||
Age (years) | (9.4) |
IBD-inflamed | HC | p value | |
---|---|---|---|
1.7 (0.3) | 0.3 (0.1) | ||
7.8 (0.9) | 0.5 (0.1) | ||
1248 (231) | 430 (43) | ||
10918 (767) | 11808 (711) | 0.52 | |
47.1 (3.1) | 66.3 (3.3) | ||
52.8 (3.2) | 32.1 (4.1) |
Responders | Nonresponders | p value | |
---|---|---|---|
2.5 (0.6) | 1.7 (0.6) | 0.9 | |
10.1 (1.5) | 4.7 (1.2) | ||
1595 (523) | 552 (40) | 0.2 | |
12182 (3613) | 6693 (3614) | ||
61.4 (7.0) | 34.8 (6.5) | ||
38.4 (7.1) | 65.2 (2.7) | ||
1.6 (0.4) | 0.9 (0.3) | 0.2 | |
9.7 (1.6) | 4.2 (1.0) | ||
1452 (434) | 1019 (335) | 0.5 | |
13152 (1319) | 10983 (1368) | 0.3 | |
50.8 (4.9) | 50.2 (9.9) | 0.9 | |
49.2 (4.5) | 49.8 (9.9) | 0.9 |